Search Results - "Sofrygin, O"

Cost–effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate by Vera-Llonch, M., Massarotti, E., Wolfe, F., Shadick, N., Westhovens, R., Sofrygin, O., Maclean, R., Yuan, Y., Oster, G.

“…Objective. To assess cost–effectiveness of abatacept in patients with moderately to severely active RA and inadequate response to MTX. Methods. We developed a…”
Get full text

2135 POSTER Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with ErbB2+ (HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective by Delea, T.E, Tappenden, P, Sofrygin, O, Karnon, J, Amonkar, M, Browning, D, Rudge, H, Walker, M

Get full text

Cost of Current Iron Chelation Infusion Therapy and Cost-Effectiveness of Once-Daily Oral Deferasirox in Transfusion-Dependent Thalassemia Patients in Canada by Delea, T.E., El Ouagari, K., Sofrygin, O.

“…Background: Deferasirox (Exjade®) is a recently approved once-daily oral chelator that has been shown to produce reductions in liver iron concentrations and…”
Get full text

PCN105 PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR LETROZOLE ALONE by Delea, TE, Sofrygin, O, Amonkar, M

Get full text

Cost-effectiveness of lapatinib plus capecitabine (LAP+C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ+C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the U.K. National Health Service (NHS) perspective by Sofrygin, O., Delea, T. E., Tappenden, P., Karnon, J., Browning, D., Amonkar, M., Lykopoulos, K., Cameron, D. A.

“…Abstract only…”
Get full text

Cost-effectiveness of zoledronic (ZOL) acid plus endocrine therapy (ET) in premenopausal women with early breast cancer (EBC) from a Canadian perspective by Ougari, K. E., Taneja, C., Sofrygin, O., Kaura, S., Delea, T.

“…Abstract only 557 Background: The Austrian Breast and Colorectal Cancer Study Group Trial 12 (ABCSG-12) examined the efficacy of 3 years (yrs) of treatment…”
Get full text

Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with early stage breast cancer based on results of the ABCSG-12 study by Delea, TE, Taneja, C, Sofrygin, O, Kaura, S, Gnant, M

“…Abstract Abstract #2112 Background: Zoledronic acid (ZOL) has demonstrated antitumor and antimetastatic activity in preclinical and early clinical studies. The…”
Get full text

Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with HER2+ metastatic breast cancer (MBC) who received prior therapy with trastuzumab (TZ) based on updated survival data from EGF100151 by DeLea, T., Tappenden, P., Sofrygin, O., Karnon, J., Amonkar, M., Browning, D., Rudge, H. J., Walker, M. D.

“…Abstract only…”
Get full text

PCN71 COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT) by Delea, T, Sofrygin, O, Tappenden, P, Browning, D, Amonkar, MM, Karnon, J, Lykopoulos, K

Get full text

PCN21 COST-EFFECTIVENESS OF LAPATINIB PLUS CAPECITABINE FORWOMEN WITH HER2+ METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TRATSTUZUMAB IN FINLAND by Färkkilä, N, Torvinen, S, Bergius, S, Delea, T, Sofrygin, O, Walker, M

Get full text

PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY) by Sofrygin, O, Delea, T, Tappenden, P, Karnon, J, Amonkar, MM, Walker, M

Get full text

PMH30 HEALTH CARE BURDEN OF PATIENTS WITH ALCOHOL DEPENDENCE SYNDROME by Weycker, D, Erder, MH, Edelsberg, J, Holder, H, Sofrygin, O, Oster, G

Get full text

PHM1 COST-EFFECTIVENESS OF ONCE-DAILY ORAL CHELATION THERAPY WITH DEFERASIROX VERSUS INFUSIONAL DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS by Delea, T, Sofrygin, O, Thomas, S, Baladi, JF, Phatak, P, Coates, TD

Get full text

PHM4 COSTS AND CONSEQUENCES OF INADEQUATE COMPLIANCE WITH DEFEROXAMINE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA by Delea, T, Sofrygin, O, Thomas, S, Baladi, JF, Coates, TD, Phatak, P

Get full text

PSY5 COST-EFFECTIVENESS OF DEFERASIROX VERSUS DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSAEMIA PATIENTS IN HONG KONG—AN INITIAL ANALYSIS by Lee, KK, Chow, DP, Lau, H, Pramanik, A, Delea, TE, Sofrygin, O, Shi, W

Get full text